Dexmedetomidine effect in reducing pain in sleeve gastrectomy

Evaluation of the effect of celiac plexus block using intraoperative dexmedetomidine to reduce pain in sleeve gastrectomy patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250902067095N2

Enrollment

Registered

2026-05-06

Start date

2026-06-06

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleeve gastrectomy.

Interventions

Intervention 1: Intervention group: 200 micrograms of dexmedetomidine diluted to 20 ml intraoperatively before closing the surgical site, which is injected into the patient around the celiac ganglion.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Laparoscopic sleeve gastrectomy surgery candidates BMI > 35 No non-steroidal anti-inflammatory drug use over the past 2 weeks

Exclusion criteria

Exclusion criteria: American Society of Anesthesiologists class IV or V Sensitivity to dexmedetomidine

Design outcomes

Primary

Measure	Time frame
Postoperative pain. Timepoint: Recovery, 2 hours, 6 hours, 18 hours and 24 hours after surgery. Method of measurement: Numerical rating scale.	—

Secondary

Measure	Time frame
Postoperative nausea and vomit. Timepoint: Recovery, 2 hours, 6 hours, 18 hours and 24 hours after surgery. Method of measurement: Simplified PONV scoring method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKousha Farhadi

Tehran University of Medical Sciences

koushafarhadi@gmail.com+98 912 490 5702

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026